Onconostic Technologies / 3NDx

Onconostic Technologies-3N Diagnostics Group (OT/3NDx), an emerging leader in precision oncology diagnostics, today announced clinical validation of the pan-cancer, tissue agnostic utility of VERESCA based on detection of FOXC1 protein in oral cancer.

Onconostic Technologies-3N Diagnostics Group (OT/3NDx), a leader in precision oncology diagnostics, today announced study results from the Phase III GEICAM/CIBOMA clinical trial involving patients diagnosed with triple-negative breast cancer (TNBC).

Onconostic Technologies-3N Diagnostics Group (OT/3NDx), a leader in precision oncology diagnostics, today announced that new breast cancer data will be highlighted in a Rapid Oral Abstract Session at the 2024 American Society of Clinical Oncology (ASCO)..